

Original Research Article.

HYPERHOMOCYSTEINEMIA IN CHRONIC KIDNEY DISEASE PATIENTS IN A TEACHING HOSPITAL IN NIGERIA

ABSTRACT

Aim: To determine the ~~prevalence~~ prevalence of hyperhomocysteinemia amongst chronic kidney disease (CKD) patients at a Teaching Hospital in Nigeria and to determine its relationship with the severity of kidney disease.

Comment [M1]: The term prevalence was used because this was a cross sectional study.

Comment [M2]:

Study design: A ~~cross sectional study~~ cross-sectional study carried out in the department of Medicine in a Teaching Hospital in Nigeria between April 2012 and May 2013

Comment [M3]: This is not a case control study as the outcome in both groups – cases and controls wasn't known

Methodology: One hundred and thirty-eight patients with CKD and 69 healthy controls were recruited. ~~They had their estimated Gglomerular filtration rates~~ was estimated for both patients and ~~controls~~ assessed, using measured serum creatinine in the Cockcroft-Gault formula and ~~the patients were~~ were grouped into the different stages of chronic kidney disease. They also had homocysteine levels measured using the enzyme-linked immunosorbent assay ~~and these~~ Homocysteine levels were also compared in the different chronic kidney disease stages.

Results: A hundred and thirty-eight chronic kidney disease- patients participated in this study, of which 3 each (~~2.2 2~~%) were in CKD stages 1 and 2, 46 (33.3%) in stage 3, 66 (47.8%) in stage 4 and 20 (14.5%) in stage 5. The ~~patients~~ mean age ~~of the patients~~ was 45.9 ± 16.5 years and 42.3 ± 14.7 years for control subjects. The prevalence of hyperhomocysteinemia was 57.9% amongst cases and 4.3% amongst control subjects with median homocysteine (Hcy) level being $19.1 \mu\text{mol/l}$ (IQR - 13.8) in cases and $8.3 \mu\text{mol/l}$ (IQR - 2.9) in controls, this was significant ($P < .001$) with the chronic kidney disease patients having higher median homocysteine levels as the degree of kidney disease worsened.

Conclusion: The ~~prevalence~~ prevalence of hyperhomocysteinemia is high in CKD patients compared to controls and it ~~s prevalence and severity~~ increases as CKD progresses.

27 Keywords: chronic kidney disease, homocysteine, hyperhomocysteinemia, cardiovascular
28 disease

29 INTRODUCTION

30 Chronic kidney disease (CKD) is a public health problem ~~that is present~~ present
31 worldwide with an incidence that's on the rise, unfavourable outcomes and very high cost
32 [1].

33 Cardiovascular disease (CVD) ~~is a~~ major cause of morbidity and mortality in patients
34 with CKD ~~that~~ which is well documented ~~is cardiovascular disease (CVD)~~ [2]. Although patients
35 with CKD are at risk of ultimately developing end- stage renal disease (ESRD), about 50% of
36 CKD patients die of CVD before commencement of dialysis [3-6]. ~~The morbidity and mortality~~
37 ~~from CVD is extremely high in CKD~~ In patients requiring haemodialysis ~~patients~~ (usually stage
38 5 CKD ~~patients~~) ~~the morbidity and mortality from CVD is extremely high~~ [7]. Based on data
39 from the U.S. Renal Data System Coordinating Center Case-Mix Adequacy Study, clinical
40 coronary heart disease (CHD) is seen in 40% of haemodialysis patients and CVD in them is 10 to
41 30 times higher than in the general population despite stratification by gender, age, race, and the
42 presence of diabetes [7].

43 CKD patients usually develop accelerated atherosclerosis and the risk of premature death
44 from CVD is higher ~~in them~~. The predisposition of these patients to atherosclerosis ~~is increased~~
45 ~~and~~ is driven mainly by inflammation, dyslipidemia and oxidative stress, and these are features
46 associated usually with CKD [2]. Chronic inflammation is prevalent in CKD patients and
47 numerous studies have demonstrated that chronic inflammation may be a contributor to the
48 morbidity and demise among end stage renal disease (ESRD) patients [8, 9]. The increased
49 cardiovascular morbidity and mortality among CKD patients may not be fully explained by
50 conventional risk factors.

Formatted: Font: (Default)
MingLiU_HKSCS-ExtB, English (United States)

51 A number of abnormalities in the metabolism of protein and amino acid are seen in
52 patients with CKD especially ESRD, an increase in the plasma concentration of homocysteine, a
53 sulphur containing amino acid is one of such abnormalities that may be seen[10].

54 Homocysteine is associated with inflammation and is been considered as an
55 inflammatory marker [11,12]. It acts as an atherogenic and thrombophilic agent which
56 potentiates hypertension and smoking as well as other risk factors that predispose to peripheral
57 arterial disease [10]. ~~##All~~ of which increase morbidity as well as mortality in CKD patients.
58 Hence homocysteine is attracting a lot of attention among renal patients.

59 Hyperhomocysteinemia in itself has also been shown to be an independent
60 cardiovascular risk factor in patients with chronic kidney disease [10, 13] however, the
61 mechanism is not clear. Elevated levels of homocysteine and cardiovascular disease are common
62 in patients with decreased renal function. An increase in ~~Homocysteineey~~ represents a potent
63 risk factor for coronary, cerebrovascular and peripheral arterial disease as well as for deep vein
64 thrombosis [14]. Hyperhomocysteinemia is seen in the early stages of CKD at levels of
65 glomerular filtration rate (GFR) of about 60ml/min and its prevalence increases to about 85-
66 100% ~~+15~~ in ESRD[15]. In the general population moderate hyperhomocysteinemia is seen in
67 approximately 5 – 7 % [16].

68 The burden of CKD in terms of morbidity and mortality is huge, worse in developing
69 countries where access to, and affordability of care is not readily available. A major factor
70 contributing to this burden is CVD. To reduce this burden, cardiovascular risk factors ~~in~~ CKD
71 patients must be sought and addressed. The paucity of data on hyperhomocysteinemia in chronic
72 kidney disease in a developing country like ~~Nigeriaours~~ necessitated this study.

73 **MATERIALS AND METHODS**

74 This was a hospital-based cross sectional ~~ross sectional comparative~~ study carried out in
75 the Nephrology unit, in a tertiary hospital in Nigeria. Patients presenting at the Nephrology
76 clinic/Dialysis/Accident and Emergency units who met the inclusion criteria -adults above 18
77 years of age in CKD stages 1 – 5, on conservative or renal replacement therapy and who gave
78 their consent, were consecutively recruited. Exclusion criteria were patients below 18 years of
79 age, non-consenting patients, patients on methotrexate, phenytoin or theophylline therapy,
80 menstruating women, patients with acute kidney injury, hypothyroidism, acute lymphoblastic
81 leukemia and cancers of the breast, ovaries and pancreas. Controls were recruited from amongst
82 hospital staff (doctors and nurses) who were apparently healthy and not on medication for any
83 acute or chronic ailments. Approval for the study was obtained from the Ethics and Research
84 Committee of the hospital. All participants gave written informed consent.

Formatted: English (United States)

85 **SAMPLE SIZE**

86 Studies on the prevalence of hyperhomocysteinemia revealed a range of 56% - 90% [7, 10, 16,
87 19, 20, 21]. The sample size was extrapolated from the formula for sample size determination in
88 an infinite population [22] using a prevalence of 90% and a degree of precision of 0.05. A
89 sample size of 138 was arrived at. A total of 138 chronic kidney disease patients and 69 controls
90 in a ratio 2:1 were recruited for this study.

Comment [M4]: A ratio 2:1 was used to minimise cost

91 Upon recruitment, a researcher administered questionnaire was completed. Data on
92 physical characteristics such as weight, height, hip and waist circumference and blood pressure
93 were recorded. Weight was measured in kilograms using hospital health scale ZT-120 with
94 patients putting on light clothing without foot wears. The height was measured in meters using
95 the same scale. The body mass index BMI defined as weight in kilogram divided by the square
96 of patient's height in meters was calculated. The waist circumference in centimetres was
97 measured in the horizontal plane at the level of the natural waist line taken to be at the umbilicus

98 | using a non-stretchable tape. All patients and controls were instructed to be on~~observe an~~
99 | overnight fast for 8-10 hours before blood~~the day of~~ sample collection on the next day. About
100 | 10ml of venous blood was collected, 5ml into a lithium heparin sample bottle for serum
101 | creatinine estimation using the Jaffe's reaction and 5ml into an EDTA bottle and centrifuged for
102 | 15 minutes within 30 minutes of collection and plasma stored at < 20oC for homocysteine level
103 | assay using the Axis® Homocysteine FHCY100 Enzyme Immunoassay (EIA) [17].

104 | The results were categorized~~interpreted~~ as follows:- moderate hyperhomocysteinemia -
105 | 15-30µmol/L, intermediate hyperhomocysteinemia - >30-100µmol/L, and severe
106 | hyperhomocysteinemia - >100µmol/L [16].

107 | Fasting blood sugar (FBS) was measured using an Accucheck glucometer and strips. The
108 | ~~controls had same done.~~

109 | Glomerular filtration Rate R~~—~~ was calculated using the Cockcroft-Gault formula to
110 | estimate creatinine clearance (CCr): $CCr = (140 - \text{age}) \times (\text{weight})/72 \times SCr \times (0.83 \text{ if female})$,
111 | where SCr is in mg/ dL, weight in kg and age in years and results were stratified according to the
112 | KDIGO guidelines [17] into CKD the different stages 1-5 of CKD.

113 | **SAMPLE SIZE**

114 | ~~Studies on the prevalence of hyperhomocysteinemia revealed a range of 56%–90% [7, 10, 16,~~
115 | ~~19, 20, 21]. The sample size was extrapolated from the formula for sample size determination in~~
116 | ~~an infinite population [22] using a prevalence of 90% and a degree of precision of 0.05. A~~
117 | ~~sample size of 138 was arrived at.~~

118 | **DATA ANALYSIS**

119 | Data entry, storage, and management were performed on the statistical software package
120 | for Social Sciences (SPSS) version 17.

121 ~~Results were presented in tabular and graphical forms. A univariate analysis describing~~
 122 ~~the baseline socio demographic characteristics of participants and prevalence rate were done.~~
 123 ~~Continuous variables that are~~ Normally distributed continuous variables were presented as means
 124 and standard deviation (SD) and skewed data as medians with inter-quartile ranges (IQR) or
 125 standard deviation ~~while ds.~~ Discrete variables were presented as percentages. The student t-test
 126 was employed for comparing the means of data with normal distribution while Wilcoxon Signed
 127 Ranks was used for skewed data in cases versus controls. Chi-square was used in testing for
 128 significant differences between proportions and frequencies of cases and controls that had
 129 hyperhomocysteinemia.

130 The confidence interval was set at 95% limit, with a level of significance, $P < 0.05$.

131 **RESULTS**

132 ~~A total of 138 chronic kidney disease patients and 69 controls in a ratio 2:1 were~~
 133 ~~recruited for this study.~~ Their ages of patients ranged from 18 to 80 years with the mean age of
 134 the study population being 45.9 years \pm 16.4 for cases and 42.2 years \pm 14.6 for control (P
 135 $=0.119$). The cases consisted of 89 males (64.5%) and 49 females (35.5%) while controls were
 136 made up of 42 males (60.9%) and 27 females (39.1%), $P = 0.610$

137 There was no statistically significant difference between mean ages, sex and marital status of
 138 cases and controls as shown in table I.

139 **TABLE 1:** SOCIODEMOGRAPHIC CHARACTERISTICS OF STUDY POPULATION

	CASES	CONTROLS	t	P -value
CHARACTERISTICS	n = 138	n = 69		
	<u>(Mean \pm S.D)</u>	<u>(Mean \pm S.D)</u>		

Formatted: Border: Between : (Single solid line, Auto, 0.5 pt Line width, From text: 1 pt Border spacing:)

Formatted: Font: Not Italic

Formatted Table

	(Mean ± S.D)	(Mean ± S.D)		
Age	45.9 ± 16.4	42.2 ± 14.6		0.119
Age	45.9 ± 16.4	42.2 ± 14.6	1.570	0.119
	<u>n = 138(%)</u>	<u>n = 69(%)</u>	<u>X²</u>	
Sex				
Male	89 (64.5%)	42 (60.9%)	<u>0.260</u>	0.610
Female	49 (35.5%)	27 (39.1%)		
Marital status				
Single	34 (24.6%)	15 (21.7%)	=	<u>-0.188</u>
Married	92 (66.7%)	53 (76.8%)		
Divorced	9 (6.5%)	1 (1.4%)		
Widowed	3 (2.2%)	0 (0.0%)		

Formatted: Left

Formatted: Left

Formatted: Font: Bold

Formatted: Font: Not Bold

141 Table II shows the mean BMI, waist-hip ratio (WHR), FBS, estimated GFR and
 142 homocysteine levels in cases and controls. The homocysteine and FBS levels were significantly
 143 higher in the patients ($P < .001$), while the estimated GFR was significantly lower in cases.

144 **TABLE 2H:** CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF STUDY
 145 POPULATION

VARIABLE	CASES (n=138)	CONTROLS (n=69)	TEST STATISTICS _t	P- value
BMI (kg/m ²)	23.71 ± 4.94	26.7 ± 3.6	4.987 [‡]	0.762
Waist-Hip Ratio	0.92 ± 0.07	0.90 ± 0.45	0.562 [‡]	0.575
Fasting Blood Sugar (mg/dl)	107.2 ± 34.0	92.6 ± 9.9	4.637 [‡]	< 0.01
	<u>Median (IQR)</u>	<u>Median (IQR)</u>	<u>Wilcoxon</u>	<u>P- value</u>
Estimated GFR (mg/dl)	29.9(IQR-18.9)	96.7(IQR-16.7)	187.00 [‡]	<0.01
Homocysteine level(μmol/L)	19.0(IQR- 13.8)	8.3(IQR - 2.9)	1820.00 [‡]	<0.01

Formatted Table

146 * t-test

147 ‡ Wilcoxon

148 BMI – Body Mass Index, GFR – Glomerular filtration rate

149

150 Three (2.2 %) of the patients with CKD were in stage 1, another three (2.2%) were in
 151 stage 2, 46 (33.3%) in stage 3, 66 (47.8%) in stage 4 and 20 (14.5%) in stage 5. ~~The majority of~~
 152 ~~the case population were in stage 4 (47.8%).~~


153 The ~~frequency prevalence~~ of hyperhomocysteinemia was 57.9% among CKD patients and
 154 4.3% among the controls $P < 0.01$, OR = 30.34 (95% CI = 9.09,- 101.29). Forty-two percent of
 155 the CKD patients had normal levels of homocysteine, 30.4% moderate hyperhomocysteinemia
 156 and 27.5% intermediate hyperhomocysteinemia. None had severe hyperhomocysteinemia as
 157 depicted in table [3III](#).

159 **TABLE 3III: COMPARISM OF PREVALENCE OF HOMOCYSTEINEMIA (CASES**
 160 **VERSUS CONTROLS)**

	CASES	CONTROL
Elevated	80(57.97%)	3(4.35%)
Normal	58(42.03%)	66(95.65%)
Total	138(100%)	69(100%)

161 **df = 2, P- value <0.01, OR = 30.34 (95% CI = 9.09,- 101.29)**

162 The median values of Hcy increased from stage 1 to 5. There was a significant correlation
 163 between the stages of CKD and the degree of homocysteine levels (spearman's rho = 0.204, $P =$
 164 0.016-) as shown on figure 1.



167 | Fig 14: Boxplot showing correlation between CKD stage and median homocysteine levels

168 | **DISCUSSION**

169 | Increased cardiovascular morbidity and mortality in CKD patients has been associated
 170 | with elevated homocysteine levels which is a common finding in them [10,11]. This study
 171 | shows that hyperhomocysteinemia is significantly higher ~~common~~ among CKD patients. Using
 172 | the classification by Kang et al, 57.9% of the CKD patients had hyperhomocysteinemia. This is
 173 | comparable with 56% reported by Menon Vandana ~~et al~~ in England in which baseline

174 | ~~homocysteine~~Hcy was measured in 2 different populations; population A with estimated GFR
175 | 25 – 55 ml/min had a prevalence of hyperhomocysteinemia of 56% [21]. It is, however, lower
176 | than that reported by Ajith *et al* in New York [23], in which 147 patients; 85 males and 62
177 | females aged 58 ±15 years requiring hemodialysis had a prevalence of 82%. The difference in
178 | prevalence rate may be due to the fact that the index study assessed the prevalence in both
179 | dialyzing and non-dialyzing patients.

180 | Of the number of cases with hyperhomocysteinemia, 30.452.5%, and 247.5% had
181 | moderate and intermediate hyperhomocysteinemia respectively, none had severe
182 | hyperhomocysteinemia, which is not surprising as cases of severe hyperhomocysteinemia usually
183 | due to homozygous defects in genes encoding for enzymes of homocysteine metabolism leading
184 | to accumulation of Hcy in blood and urine, are extremely rare. An example of this is a disorder
185 | caused by homozygosity for a defective gene which encodes for cystathionine beta-synthase. In
186 | this condition Hcy can be as high as 400umol/L [24]. In the index study, however, a majority of
187 | the patients with hyperhomocysteinemia had moderate hyperhomocysteinemia which may be due
188 | to deficiencies in vitamins that play major roles in Hcy metabolism, depending on the arm of the
189 | 2 metabolic pathways that is defective, that is vitamin B12 and folate deficiency in the
190 | remethylation pathway. These vitamins may be lacking in CKD patients as renal disease results
191 | in a catabolic state, a syndrome of malnutrition, inflammation and atherosclerosis with reduced
192 | intake and minimal absorption usually prevalent in patients especially those in end-stage [25].

193 | ~~The A-significant difference was noticed in tHcy homocysteine levels between~~ cases
194 | and control ~~in this study which was higher in the cases than control, which is also~~ in keeping
195 | with the findings by Muhammad *et al* in Pakistan [26]. The mean tHcy value of the controls 8.3
196 | ± 2.85 is also comparable to that reported by Okubadejo *et al* amongst their control subjects –

Comment [M5]: Lines 143 – 145 under results shows this.

197 10.1 ± 7.7 [27] and also with that reported by Osunkalu amongst otherwise healthy subjects with
198 a mean tHcy of 9.5 ± 2.4 [28]. This is expected as the kidneys help in clearing homocysteine,
199 and with kidney disease the renal clearance of homocysteine is impaired.

200 | This study also revealed an association between the severitydegree of kidney disease and
201 | the level of hyperhomocysteinemia as it shows a steady rise in the prevalence rate of total
202 | hyperhomocysteinemia from CKD stage 1 through to 5. This association was significant; and is
203 | in concordance keeping with findings from other studies [10, 29, 30, 31]. Shankar *et al* found
204 | that higher plasma homocysteine levels were seen in patients with CKD, independent of BMI,
205 | smoking, diabetes mellitus, hypertension, cholesterol levels, and other confounders. Pooled data
206 | from 41 trials and 27,000 patients show that homocysteine levels are significantly inversely
207 | correlated with estimates of GFR [32], with higher levels of homocysteine seen in patients with
208 | reduced GFR. This inverse correlation is even more robust when using clearance methods in
209 | measuring GFR [32].

Comment [M6]: Estimated GFR is used in the staging of CKD.

210 | There is good evidence that normal kidneys play a major role in amino acid and Hcy
211 | clearance and metabolism however it may be difficult to identify the source of clearance defect
212 | of Hcy owing to the lack of data on Hcy extraction and metabolism by diseased kidneys. The
213 | existence of Hcy-metabolizing enzymes and uptake systems in renal tubular cells has been
214 | confirmed, and Hcy extraction studies in animal kidneys documented significant Hcy uptake [33,
215 | 34]. Logically the loss of metabolically active kidney tissue normally involved in Hcy handling
216 | should decrease Hcy clearance and increase plasma levels. The inverse relationship between Hcy
217 | levels and GFR, which is consistent throughout the different stages of CKD, supports the fact
218 | that it is reduced renal function, not the accumulation of uremic toxins that causes Hcy levels to
219 | increase.

220

221

222 **CONCLUSION**

223 This study has shown that hyperhomocystienemia is prevalent in CKD patients and worsens as
224 renal function declines.

225 **REFERENCES**

- 226 1. Toshiharu N, Yutaka K, Michiaki K, Yumihiro T, Keiichi T, Okubo K, *et al.*
227 Hyperhomocysteinemia and the development of chronic kidney disease in a general
228 population. *The Hisayama study. Am J. Kid Dis* 2004; 44 (3); 437-445
- 229 2. Vasilis T, Evangelia D, Kostas CS, Dyslipidemia in Chronic Kidney Disease: An
230 Approach to Pathogenesis and Treatment. *Am J Nephrol* 2008;28 :958-973
- 231 3. Keith D, Nicholls G, Guillion C. Longitudinal follow-up and outcomes among a
232 population with chronic kidney disease in a large managed care organization. *Arch Intern*
233 *med* 2004; 164: 659-663.
- 234 4. Rohm DD. Is atherosclerosis accelerated in haemodialysis patients? *Int. J. Artif. Organs.*
235 1992;15:323-326.
- 236 5. Charnwy DI, Walton DF, Cheung AK. Atherosclerosis in chronic renal failure. *Curr.*
237 *Open. Nephrol. Hypertens.* 1993; 2:876-882.
- 238 6. Vasilis T, Zoi M, Moses E. Dyslipidemia associated with Chronic Kidney Disease. *Open*
239 *Cardiovasc Med J.* 2011;5:41-48.
- 240 7. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk
241 factors of ischemic heart disease in chronic uremia. *Kidney Int* 1996;49:1428 –34.

- 242 8. Shindler R. Causes and therapy of microinflammation in renal failure. *Nephrol Dial*
243 *Transplant* 2004;19:34-40
- 244 9. Chertow GM, Soroko SH, Paganini EP, Cho KC, Himmelfarb J, Ikizler TA et al.
245 Mortality after acute renal failure: models for prognostic stratification and risk adjustment.
246 *Kidney Int* 2006;70:1120-1126
- 247 10. Guldener C. Why homocysteine is elevated in renal failure and what can be expected
248 from homocysteine lowering. *Nephrol Dial Transplant* 2006; 21: 1161-1166.
- 249 11. Nosratole DV, Mohamad N, Alan MF. HDL Metabolism and activity in Chronic Kidney
250 Disease. *Nat Rev Nephrol* 2010;6:287-296.
- 251 12. James T. Wu. Circulating Homocysteine Is An Inflammation Marker And A Risk Factor
252 of Life-Threatening Inflammatory Diseases. *J Biomed Lab Sci* 2007;19:107 – 111.
- 253 13. Guidelines for Homocysteine in Chronic Kidney Disease patients. *Indian J. Nephrol* 2005;
254 15(1):S63 – 64.
- 255 14. Herrmann W: The importance of hyperhomocysteinemia as a risk factor for diseases: an
256 overview. *Clin Chem Lab Med* 2001;39:666-74.
- 257 15. Vesna L, Petar K , Zeljko R. Characteristics of hyperhomocysteinemia in dialysis patients.
258 *Acta Med Croatica* 2006; 60(1):21-6.
- 259 16. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for
260 occlusive vascular disease. *Annu Rev Nutr* 1992;12:279-298
- 261 17. KDIGO CPG on CKD *Kidney Int Suppl* 2013; 3(1)
- 262 18. Methods and composition for assaying homocysteine.
263 <https://www.google.com/patents/US8476034>
- 264 19. Dennis VW, Robinson K, Homocysteinemia and Vascular disease in End Stage renal
265 disease. *Kidney Int Suppl*, 1996;57:S11 – 7.

- 266 20. Suliman ME, Lindholm B, Barary P, Begstrum. J. Hyperhomocysteinemia in CRF patients
267 in relation to nutritional status and cardiovascular disease. *Clin Chem Lab Med* 2001;
268 39(8):734 – 8.
- 269 21. Menon V, Wang X, Greene T, Beck G J, Kusek JW, Selhub J. et al. Homocysteine in
270 chronic kidney disease: Effect of low protein diet and repletion with B vitamins. *Kidney.*
271 *Int.* 2005;67:1539–1546.
- 272 22. Hassan T. Inferential statistics. In: Bankole MA (Ed) *Handbook of Research Methods in*
273 *Medicine.* National Postgraduate Medical College of Nigeria. 1991; 171-211.
- 274 23. Ajith PN, Dmitry N, Michael K, Eliza BG . Elevated homocysteine levels in patients with
275 end-stage renal disease. *Mt Sinai J Med* 2005;72(6):365-73.
- 276 24. Urquhart BL, House AA. Assessing plasma total homocysteine in patients with end-stage
277 renal disease. *Perit Dial Int* 2007; 27:476–48.
- 278 25. Bostom A.G, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence,
279 etiology, and potential relationship to arteriosclerotic outcomes. *Kidney. Int,*1997, 52: 10-
280 20.
- 281 26. Muhammad A, Asim M, Muhammad I, Seemab M S, Aneela A. Effect of Anaemia and
282 Hyperhomocysteinemia on Mortality of Patients on Hemodialysis. . *Iran J Kidney Dis*
283 2005; 4 (1): 60-5. 76.
- 284 27. Okubadejo NU, Oladipo OO, Adeyomoye AA, Awosanya GO, Danesi MA Exploratory
285 study of plasma total homocysteine and its relationship to short-term outcome in acute
286 ischaemic stroke in Nigerians. *BMC Neurol.* 2008;12;8:26.
- 287 28. Osunkalu V.O., Onajole AT, Odeyemi KA, Ogunnowo BA, Sekoni AO, Ayoola GA, *et al*
288 Homocysteine and folate levels as indicators of cerebrovascular accident. *J Blood Med.*
289 2010;1:131–134.

- 290 29. Shankar A, Wang JJ, Chua B, Rochtehnia E. Positive association between plasma
291 homocysteine level and Chronic Kidney Disease. *Kidney Blood Press Res* 2008; 31(1):
292 55-62.
293
- 294 30. Nerbass FB, Draibe SA, Feiten SF, Chiarello PC. Homocysteine and its determinants in
295 non-dialyzed chronic kidney disease patients. *J Am Diet Ass.* 2006; 106 (2): 267-70.
296
- 297 31. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular
298 filtration rate on plasma total homocysteine concentration. *Scand J Clin Lab Invest.*
299 1996;56(1):41-6.
- 300 32. Kielstein J.T, Salpeter R.S, Buckley N.S, Cooke J.P, Danilo F. Two Cardiovascular Risk
301 Factors in One? Homocysteine and Its Relation to Glomerular Filtration Rate A Meta-
302 Analysis of 41 Studies with 27,000 Participants. *Kidney Blood Press Res* 2008;31:259-
303 267.
- 304 33. Friedman A.N., Bostom A.G, Selhub J., Levey A.S, Rosenberg I.H. The kidney and
305 homocysteine metabolism. *J Am Soc Nephrol* 2001,12: 2181-2189.
- 306 34. Marti F, Vollenweider P, Marques-Widal P, Mooser V, Waeber G, Paccaud F et
307 al. Hyperhomocysteinemia is independently associated with albuminuria in the population
308 based CoLaus study. *BMC Public health* 2011,11:7331.